CAPSTONE COMPANIES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CAPSTONE COMPANIES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $143.3K | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $192.2K | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $346.5K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $685.9K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.77M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $12.40M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $12.83M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $36.75M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $30.63M | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | $15.92M | Mar 28, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $105.3K | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($265.6K) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($602.5K) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $47.2K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $503.8K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.43M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.89M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $8.84M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $7.40M | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | $3.82M | Mar 28, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($920.2K) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($962.4K) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($1.70M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($2.66M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($1.96M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.38M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($891.7K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.01M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $2.08M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.82M | Mar 28, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.07M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($995.8K) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($1.63M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($2.92M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($2.36M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($3.09M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($932.9K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.24M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.23M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.34M | Mar 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.2K | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $6.2K | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $101.4K | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $203.8K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $308.8K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $249.9K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $348.7K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $519.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $377.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $326.8K | Mar 28, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($283.0K) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($289.5K) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($614.5K) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($1.90M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($2.37M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.86M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($585.6K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $208.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.45M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $4.20M | Mar 28, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $43.0K | Mar 17, 2025 |
| FY2022 | Dec 31, 2021 | $31.9K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $13.5K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $34.1K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $53.9K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $47.6K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $53.5K | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | ($88.4K) | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | $77.6K | Mar 23, 2016 |
| FY2014 | Dec 31, 2013 | ($12.7K) | Mar 26, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.1K | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $838.1K | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $1.42M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $1.89M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $4.07M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.84M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $5.83M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $6.49M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $10.43M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $9.37M | Mar 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $518.2K | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $377.0K | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $3.67M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $2.43M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.95M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.26M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $857.8K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $594.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.61M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $4.22M | Mar 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($459.1K) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $461.1K | Apr 1, 2026 |
| FY2025 | Dec 31, 2023 | ($2.24M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2022 | ($545.4K) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $2.12M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $2.58M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $4.98M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $5.90M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $6.82M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $5.15M | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $773.2K | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $1.31M | Mar 17, 2025 |
| FY2021 | Dec 31, 2021 | $1.31M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $1.31M | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $1.94M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $1.94M | Mar 31, 2021 |
| FY2018 | Dec 31, 2017 | $1.94M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.94M | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | $1.94M | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | $1.94M | Mar 23, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.68M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($11.76M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($10.80M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($9.10M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($6.44M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($4.47M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.09M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.20M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($186.9K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($2.27M) | Mar 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.1K | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $15.9K | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $36.5K | Mar 17, 2025 |
| FY2024 | Dec 31, 2022 | $20.6K | Mar 17, 2025 |
| FY2022 | Dec 31, 2021 | $1.28M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.22M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.13M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $3.82M | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | $3.67M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $1.65M | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 17, 2025 |
| FY2018 | Dec 31, 2018 | 0 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Mar 28, 2017 |
| FY2012 | Dec 31, 2012 | 0 | Mar 27, 2013 |
| FY2012 | Dec 31, 2011 | 0 | Mar 27, 2013 |
| FY2011 | Dec 31, 2010 | 0 | Mar 13, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 17, 2025 |
| FY2018 | Dec 31, 2018 | 0 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Mar 28, 2017 |
| FY2012 | Dec 31, 2012 | 0 | Mar 27, 2013 |
| FY2012 | Dec 31, 2011 | 0 | Mar 27, 2013 |
| FY2011 | Dec 31, 2010 | 0 | Mar 13, 2012 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | 48.83M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | 48.83M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 48.83M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 48.89M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 46.30M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 46.58M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 47.05M | Mar 30, 2020 |
| FY2014 | Dec 31, 2014 | 654.01M | Mar 26, 2015 |
| FY2014 | Dec 31, 2013 | 657.76M | Mar 26, 2015 |
| FY2011 | Dec 31, 2011 | 649.51M | Mar 13, 2012 |